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Abstract 
 
Pancreatic cancer is an insidious and aggressive form of cancer, with a global 
mortality rate of nearly 98%.  Recent therapeutic endeavors have sought natural products 
with intrinsic cytotoxicity against pancreatic cancer cell lines, including a series of 
coumarin derivatives with pronounced bioactivity against pancreatic adenocarcinoma cell 
lines.  Structural variants of one such natural product, Angelmarin, provide insight into 
what structural elements are essential for specific bioactivity in nutrient-deprived 
conditions. The present study investigates the cytotoxicity of coumarin derivatives as a 
function of isoprenyl positioning, chain length, saturation and chirality. To this end, novel 
isoprenylated coumarin derivatives were synthesized and evaluated against PANC-1 cell 
lines under nutrient-deprived media (NDM) and nutrient-rich media (NRM) conditions. 
Coumarins isoprenylated at the C-4 position, with substituents of 10 and 15 carbons in 
length, exhibited LC50 values of 3.5 and 6 µM, respectively, against PANC-1 cells in 
nutrient-deprived conditions. Conversely, coumarins substituted with 10 carbon fully 
saturated or partially saturated chiral isoprenylated chains did not induce cell toxicity 
above 50% in NDM. These data implicate alkylation position as a primary structural 
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Introduction 
 
Pancreatic cancer is an aggressive and insidious form of cancer with a global 
mortality rate of 98% [1]. While pancreatic cancer is not the most common form of 
cancer, it is the fourth most common cause of cancer-related deaths in the United States, 
in both men and women (Figure 1A, [2]). Typically, patients have less than a 5% survival 
rate within five years of their initial diagnosis (Figure 1B, [2]). 
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Figure 1. U.S deaths and survival rates attributed to different forms of cancer in 2006. 
Both men and women are considered in the data. (A) U.S deaths attributed to different 
forms of cancer, categorized by site of tumor origin. (B) U.S survival rates, within 5 
years of diagnosis, attributed to different forms of cancer, categorized by site of tumor 
origin. Figures are reprinted from The Pancreas Center website, maintained by the 
Columbia University Department of Surgery [2]. 
 
 
The dismal survival rate associated with pancreatic cancer can be attributed to both 
the aggressive nature of the cancer, as well as its resistance to current therapies. In the 
A 
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early stages of the disease most patients are asymptomatic, which often results in late-
stage diagnosis and thus poor prognosis. Patients with the most common form of 
pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), experience a median 
survival time of just 6 months after diagnosis [3]. Pancreatic cancer cells are also 
remarkably resistant to conventional cancer therapies [4, 5].  Given that most patients are 
diagnosed in the advanced stages of the disease, surgical resection and radiation therapy 
are often implausible treatment options. Combinatorial treatment, in which multiple 
chemotherapeutic agents are used in concert, can improve median survival rate; though, 
at a taxing physical cost for the patient. To date, only 11 drugs have been approved for 
the treatment of pancreatic cancer, four of which are based on a compound (fluorouracil) 
that was described more than 50 years ago [6].  The absence of novel clinical treatments 
has prompted the search for natural products with intrinsic bioactivity against pancreatic 
cancer cells. More recent therapies boast innovative biochemical targets, such as tyrosine 
kinase inhibitors and nucleic acids that are required for cell division in an effort to 
differentially target the rapidly dividing cancer cell [6, 7]. Nevertheless, pancreatic cancer 
survival rates remain low. We propose that the notable resistance of pancreatic cancer 
cells to nutrient deprivation and hypoxia raises the possibility of a new drug target [8].  
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Figure 2. Austerity of pancreatic adencarcinoma (PANC-1) cell lines in nutrient-deprived 
conditions. (A) PANC-1 cell survival in the presence (A) and absence (B) of dialyzed 
fetal bovine serum, with the addition of (white circle) glucose and amino acids; (filled 
circle) glucose; (white square) amino acids; and (filled square) no nutrients. (B) Survival 
of various forms of cancer in the absence of nutrients or fetal bovine serum (A) liver 
cancer cell lines, (B) pancreatic cancer cell lines, (C) stomach cancer cell lines, and (D) 
colon cancer. Pancreatic cancer cell lines are highlighted in red. Figure adapted from 
Izuishi, et al [8]. 
 
 
In 2000, Izuishi and colleagues demonstrated the unique austerity of pancreatic 
cancer cells in nutrient deprived conditions (Figure 2, [8]). Pancreatic adenocarcinoma 
(PANC-1) cells remained essentially 100% viable when cultured in fetal bovine serum in 
the absence of supplemental amino acids and glucose (Figure 2Aa, [8]). In fact, 
appreciable numbers pancreatic cancer cells survived for up to three days without any 
form of nutrients (Figure 2, [8]). Significantly, when compared to other forms of cancer, 
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pancreatic cell lines are more tolerant of nutrient deprivation (Figure 2B, [8]). This 
austerity in nutrient deprived conditions is thought to underlie the unremitting nature of 
pancreatic tumors. As tumors grow, they become decreasingly innervated by blood 
vessels, and thus deprived of nutrients and oxygen. Nutrient deprivation and hypoxia, in 
turn, can lead to increased mutagenesis and genomic instability, increasing the incidence 
of cancerous growths [9]. As such, recent therapeutic endeavors have focused attention 
on natural products with intrinsic cytotoxicity against pancreatic cancer cell lines in 
nutrient deprived conditions.  
Historically, natural products have been of considerable medicinal interest due to 
their high solubility and low toxicity when compared to synthetic compounds [10].  In the 
1950’s, the United States began investigating naturally occurring compounds with 
intrinsic bioactivities against cancerous malignancies. Such endeavors led to the 
discovery of Taxol, once the most widely prescribed chemotherapy drug in the world 
[11]. Ongoing global efforts have led to the discovery of numerous natural products that 
serve as lead compounds in the development of therapies for cancerous tumors. The 
discovery process begins with crude extracts being isolated from the roots or leaves of 
plants with traditional medicinal uses and tested against a diverse selection of cancer cell 
lines. Structures with promising bioactivities are then characterized and isolated to then 
serve as parent compounds in a series of structure activity relationship (SAR) studies. In 
SAR studies, slight structural variations are made on the parent compound to determine 
the moieties that contribute to cytotoxicity. The initial structure can then be modified to 
maximize activity and specificity against the drug target, before moving further down the 
drug development “pipeline”.  
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Angelmarin (1), a natural product isolated from the root of the Japanese medicinal 
shrub Angelica pubescens in 2006, has exhibited specific and promising cytotoxicity 
against pancreatic cancer cell lines in nutrient deprived conditions (Figure 3, [12]). 
 
 
Figure 3. Angelmarin (1) and its bioactivity against PANC-1 cells in nutrient-deprived 
media (NDM). (A) The structure of Angelmarin (1) and one of its structural precursors 
(2), as determined by Awale and colleagues [12]. (B) Survival of PANC-1 cells in NDM 
at various concentrations. Both figures adapted from Awale, et al [12]. 
 
 
Within a six-hour incubation period, Angelmarin was found to kill 100% of 
pancreatic adenocarcinoma (PANC-1) at a concentration of just 10 µg/mL (Figure 3, 
[12]). Indeed, concentrations of 0.01 µg/mL were sufficient to kill all cancerous cells 
within 24 hours (Figure 3, [12]). Additionally, this bioactivity was specific to cancerous 
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cells under nutrient deprived conditions. Even at concentrations of 100 µg/mL, 
Angelmarin remained innocuous to normal cells [12]. It follows that something unique to 
the structure of Angelmarin results in the specific cytotoxicity against PANC-1 cells in 
nutrient deprived conditions, which has made it of significant interest to the medicinal 
chemistry community. Structurally, Angelmarin contains a coumarin backbone, 
substituted at the 7th and 8th positions by an alkylated furan. Interestingly, a structural 
precursor to Angelmarin (2) isolated from the A. pubescens plant did not exhibit the same 
unique bioactivity (Figure 3A, [12]). This discrepancy in activity suggests that 
preferential cytotoxicity against PANC-1 cells in nutrient deprived conditions may be 
imparted by Angelmarin’s hydrocarbon tail. 
Coumarin-based natural products isolated from the Ferula assa-foetida plant (located 
predominantly in Iran, Afghanistan and mainland China), which has traditionally been 
used to treat whooping cough and diseases of the nervous system, have also demonstrated 
remarkable cytotoxicity against a variety of cancer cell lines [13, 14]. While numerous 
coumarins have been isolated from the Ferula genus, Lee et al. recently isolated a 
number of coumarin derivatives (3, 4) with pronounced antiviral and cytotoxic character 
(Figure 4, [13, 15]). 
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Figure 4. Sampling of coumarin derivatives isolated from Ferula assa-foetida by Lee and 
colleagues [13]. These examples contain a coumarin backbone, substituted at the C-7 
position with hydrocarbon tails [13]. 
 
 
The majority of these compounds contain a coumarin scaffold that is substituted at 
the C-7 position by a farnesyl-derived moiety [13]. Again, it is likely that coumarin-
derivative anti-viral and anti-tumoral activity is a consequence of the isoprenyl coumarin 
substituents; though, in-depth mechanistic studies have yet to be performed.  
Another family of coumarins, isolated from the Kayea assamica flower, which is 
native to Myanmar, has demonstrated preferential cytotoxicity against PANC-1 cells in 
nutrient deprived conditions at concentrations of 1 µM [5]. Application of the compounds 
reported in this study can induce morphological changes in PANC-1 cells that are 
indicative of apoptosis. Interestingly, Win and colleagues proposed that an isoprenoid 
substituent at the C-8 position, in conjunction with a hydroxypropyl group at the C-4 
position led to maximal observed cytotoxicity (5) [5]. 
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Figure 5. Substructure of coumarins isolated from Kayea assamica plant by Win and 
colleagues that exhibited most potent cytotoxicity against PANC-1 cells in nutrient 
deprived conditions. 
 
Moreover, the addition of rigid structural groups at the C-4 and C-8 positions 
significantly decreased potency; whereas, the exchange of more flexible hydrocarbon 
groups such as geranyl and oxobutyl moieties at the C-6 and C-8 positions, in the 
presence of a hydroxypropyl group at C-4, retained PANC-1 cytotoxicity [5]. 
Previously, our laboratory explored the bioactivity of simplified structural coumarin 
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Figure 6. Coumarin derivative with potent bioactivity (LC50 = 6.25 µM) against PANC-1 
cells in NDM. Compound synthesized by Devji, et al [16]. 
 
 
Remarkably, we found that several simple coumarin derivatives exhibited specific 
cytotoxicity against PANC-1 cells in nutrient-deprived conditions. Indeed, coumarins 
alkylated at the C-7 position were found to kill PANC-1 cells at micromolar 
concentrations (Figure 6,7; [16]).  
 
 
Figure 7. Cytotoxicity of a series of coumarin derivatives following 24 hour incubation 
with PANC-1 cells in nutrient-deprived media. Figure from [16].  
 
The level of cytotoxicity was dependent on the identity of the substituted moiety. 
Specifically, the length of isoprenyl chains was directly correlated with increased 
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cytotoxicity against PANC-1 cells in nutrient deprived media [16]. Based on this prior 
work, the present study further investigates the cytotoxicity of coumarin derivatives 
against PANC-1 cells, and probes the underlying biological mechanisms of action of the 
coumarin-based compounds derived cytotoxicity. 
Coumarins have represented a canonical class of natural products since the early 
1800’s [17]. They are of significant medicinal interest due to their wide range of 
biological activities. To date, coumarins have exhibited varied intrinsic bioactivities, 
including: antiviral, antibacterial, antiparasitic, anti-microbial, antioxidant, anticoagulant, 
antimicrobial and anticancer properties [17, 18]. Coumarins are also known to have anti-
psychotic and anti-degenerative properties, as well as signaling capabilities at 
dopaminergic and serotinergic receptors, implicating a functional role for coumarins in 
the central nervous system [17]. Similar compounds are also known to reduce the 
accumulation of Aβ proteins in the cell and are in the clinical stage of development in the 
treatment of Alzheimer’s disease (AD) [19]. This efficacy has been attributed to 
coumarin bioactivity against acetylcholinesterase (AChE) and beta-site amyloid precursor 
protein [APP] cleavage enzyme (BACE-1) [20]. AChE is an enzyme that breaks down 
acetylcholine, reducing the available acetylcholine in the synaptic cleft. AChE has also 
been implicated in the deposition of Aβ aggregates and can induce Aβ fibril formation. 
BACE-1 is an enzyme that is necessary for the production of the Aβ protein [20]. 
Structurally, coumarins are characterized by a bicyclic, conjugated ring system with a 
lactone moiety (Figure 8). 
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Figure 8. Basic coumarin chemical structure. 
 
Coumarins can be further classified into four subgroups on the basis of their ring 
substituents: 1) simple coumarins, 2) furanocoumarins, 3) pyranocoumarins, and 4) 
bis/tri-coumarins [19]. Most naturally occurring coumarins are substituted at the 6, 7, or 8 
positions [17]. 
Despite the robust and specific bioactivities of many coumarins, few have made it to 
the clinical stage of development. This discrepancy may be attributed to the limited 
synthetic and biological availability of most coumarins [18]. Coumarins have been 
isolated from numerous plant, fruit, bacterial and animal species [17]. However, natural 
resources are limited and the purification of coumarin derivatives is a time-consuming 
process often resulting in low yields. Few total syntheses for naturally occurring 
coumarin-containing compounds have been published, largely due to the numerous 
stereogenic centers present in these complex coumarin derivatives (for example, see 8).  
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Figure 9. Natural product, 8, was isolated from the aerial root of the Angelica urumeinsis 
plant and has exhibited antioxidative properties [21].  
 
In fact, due to their structural complexity, some coumarins, like novobicin (9), must 
be biosynthetically engineered from bacterial sources [22].  
 
Figure 10. The antibiotic, Novobiocin (9).  
 
Consequently, research efforts have focused predominantly on the most synthetically 
accessible sub-class of coumarins, simple coumarins. 
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Simple coumarins are characterized by the presence of hydroxy, alkoxy and alkyl 
substituents and will be the focus of the present investigation [17]. They can exhibit 
potent bioactivities in a variety of biological conditions [16, 17]. For instance, 4-
hydroxycoumarin derivatives are known to possess more anti-coagulant activity than the 
globally produced anti-coagulant, Warfarin (10). 
 
 
Figure 11. Structure of the anticoagulant, Warfarin (10).  
 
A series of simple coumarin derivatives are known to inhibit the activity of HIV-1 
protease (HIV-PR), which is necessary for the viral life cycle; the HIV-1 integrase 
enzyme that facilitates the assimilation of viral DNA in the host cell; and human 
papillomavirus (HPV-1) [17].  The unsubstituted coumarin scaffold itself has shown to 
have low anti-bacterial activity, while the addition of hydrocarbon chains significantly 
increases efficacy. Yet another simple coumarin derivative, a disubstituted coumarin, has 
shown activity against multi-drug resistant (MDR) strains of cancer (11, [19]). 
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Figure 12. Structure of 7-Diethylamino-3(2`-benzoxazolyl)-coumarin (DBC). DBC is 
effective against multi-drug resistant (MDR) strains of various cancers [19].  
 
 
Despite the relative structural simplicity of simple coumarins, they can exhibit diverse 
bioactivities. Coumarin substituents, and not the bicyclic lactone, are thought to be 
essential for bioactivity. For instance, anti-fungal and anti-bacterial activity has been 
attributed to free hydroxyl groups at the C-6 and C-7 positions, respectively; while, the 
antioxidant properties of coumarins are directly linked to the number of free hydroxyl 
groups [19, 23]. 
The broad spectrum of coumarin-derived anticancer bioactivity may be related to its 
anti-radical and anti-oxidative properties [19]. Oxygen and nitrogen based reactive 
species are present throughout the body and are the normal byproduct of mitochondrial 
function. However, unregulated free radicals can cause oxidative stress leading to DNA 
damage, carcinogenesis and widespread cellular malfunction. Increased levels of iron, 
and thus iron ion, can also produce an excess of hydrogen peroxide, which can then lead 
to radical species production. So, coumarins are thought to be effective preventative 
cancer therapies by reducing the concentrations of free radicals and oxidative species in 
the cell, minimizing further damage to the cell [19]. It follows that coumarins may also 
constitute effective preventative treatments by reducing oxidative damage prior to 
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cancerous growth. High anti-oxidative activity has been specifically attributed to 
coumarins with minimal electron-withdrawing substituents and maximal electron density 
distribution, via resonance structures [19]. 
 There are many naturally occurring anti-oxidative compounds, including vitamins 
A and E, whose activity could be supplemented by coumarin-based treatments [19]. 
Moreover, vitamins A and E (12) are structurally similar to isoprenylated coumarins, 
perhaps implicating isoprenyl chains in antioxidative properties [24, 25]. 
 
 
Figure 13. Chemical structure of vitamin E. Figure taken from [25]. 
 
These anti-oxidative capabilities are also thought to reduce cellular oxidative stress in 
the presence of Aβ aggregates in Alzheimer’s disease (AD) and have motivated 
additional clinical trials of coumarin derivatives for Alzheimer’s patients [19, 20]. In fact, 
the natural product Umbelliferone (13) reduces free radical levels in wild-type cells by up 
to 70-80% [26]. 
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Figure 14. Chemical structure of Umbelliferone (13).  
 
 Coumarin derivatives isolated from the Torpedo californica plant have also exhibited 
inhibitory AChE activity in a reversible manner, sparking interest in the natural products 
as potential anti-AD agents. Ensaculain 1, 14, a structural analog of the coumarin 
derivatives from the T. californica plant is currently in clinical trials for AD therapy [27]. 
 
 
Figure 15. Chemical structure of Ensaculin (14).  
 
Lipophilicity has been proposed as a critical determinant of coumarin-derived 
antioxidant activity and cytotoxicity [19, 24]. Each compound’s lipophilicity is directly 
related to the length of its hydrocarbon substituents, providing a potential mechanism for 
the direct relationship between isoprenyl chain length and cytotoxicity [16]. Longer 
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carbon chains produce higher lipophilicities, thereby facilitating membrane integration. 
However, it remains unclear whether coumarins act within the cell or at the membrane 
surface. Recent work has suggested that some coumarin derivatives may, indeed, cross 
the cell membrane and act at the cell nucleus. It has been proposed that coumarin 
derivatives enter the cell and alter the cell-division cycle [28, 29]. Antitumor properties 
may also be related to apoptotic inducing elements [28]. Paradoxically, some work 
suggests that coumarin metabolites may be toxic. Different species produce different 
coumarin metabolites resulting in variable levels of cytotoxicity. In humans, coumarins 
are often reduced to innocuous 7-hydroxycoumarin derivatives; alternatively, in rodents 
coumarins are metabolized via a C-3, C-4 epoxide intermediate (15) that is toxic [30, 31].  
 
 
Figure 16. Coumarin 3,4-epoxide intermediate. A common, toxic coumarin metabolite in 
rodents [31]. 
 
Humans are regularly exposed to coumarins in beauty products and food, so some 
tolerable level of coumarin exposure does, indeed, exist [19]. 
In addition, previous work has suggested that a “set point” concentration of 
intracellular coumarin derivatives is necessary to reduce oxidative stress [19]. For 
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example, Novobicin, 9, which has emerged as a promising anti-cancer agent, is a 
coumarin derivative that demonstrates anti-tumor properties. Its activity is attributed to 
the interaction between Novobicin and heat-shock protein 90 (Hsp90), a molecular 
chaperone protein that mediates the cellular response to stress. Molecular chaperones 
have emerged as critical regulatory molecules in the evolution of cancer. The relative 
concentrations of Hsp90 and Novobicin are thought to determine Novobicin’s efficacy 
[19, 32]. Likewise, the relative concentrations of Vitamin K and Warfarin can influence 
the level of Warfarin’s anticoagulant activity [33]. 
The current study investigates the influence of isoprenyl position and chain length on 
the cytotoxicity of isoprenyl coumarins against PANC-1 cells in nutrient-deprived 
conditions. Moreover, we propose to probe the underlying mechanisms of coumarin-
derived bioactivity using fluorescence experiments. We are particularly interested in the 
structures that facilitate the selective bioactivity of coumarin derivatives in nutrient-
deprived conditions. Our immediate goals are three-fold: 1) to synthesize two novel 
series of isoprenylated coumarins: a monoprenylated series substituted at the C-4 position 
(Figure 17) and a diprenylated series substituted at the C-4 and C-7 position (Figure 18), 
2) to determine the bioactivity of these novel coumarins against healthy human fibroblast 
cells, and PANC-1 cells in nutrient-rich and nutrient-deprived conditions, and 3) to 
investigate the mechanism of coumarin cytotoxicity using fluorescence spectroscopy. 
Most naturally occurring coumarins are substituted at the 6th, 7th, or 8th carbons of the 
bicyclic structural backbone (Figure 8) and the primary coumarin metabolite in humans is 
7-hydroxycoumarin [17, 33]. Additionally, recent work from our laboratory has 
demonstrated the promising cytotoxicity of coumarins substituted at the C-7 position [16] 
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against PANC-1 cells under nutrient deprived conditions. Consequently, prior research 
efforts have focused mostly on coumarins substituted at the 6th, 7th, and 8th positions, and 
strikingly little work has been done on the activities of C-3 and C-4 substituted 
coumarins. Thus, we selected to investigate the influence of isoprenyl positioning on anti-




Figure 17. Proposed isoprenylated structures alkylated at the C-4 position (Series 1). 
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Figure 18. Proposed diprenylated structures alkylated at the C-4 and C-7 positions (Series 
2). 
 
In the present study, we will alkylate 4-hydroxycoumarin with isoprenyl moieties of 
varying length, using the Williamson Ether synthesis (Figure 19). The Williamson Ether 
synthesis employs commercially available halide starting materials and 4-
hydroxycoumarin. 
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Figure 19. Schematic of Williamson ether synthesis. Starting materials consist of 4-
hydroxycoumarin and a halogenated isoprenyl chain. 
 
The mechanism proceeds as follows: first, sodium hydride is added to 4-
hydroxycoumarin to depronate the hydroxy group; the alkyl halide is then added to the 
reaction mixture, allowing the deprotonated coumarin to displace the halide via an SN2 
reaction (Figure 19). The polar, aprotic solvent, DMF, allows the reaction to proceed in 
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good yield. The same mechanism was expected to proceed with a dihydroxy starting 
material.  
In addition to evaluating the bioactivities of C-4 substituted coumarins, we will 
investigate the cytotoxicity of diprenylated coumarins, with substituents at the C-4 and C-
7 positions and monosubstituted coumarins with saturated and partially saturated, chiral 
isoprenyl tails (Figures 19 and 20). These findings will inform our understanding of the 
effect of chirality, saturation and the introduction of an additional isoprenyl moiety on the 
underlying molecular mechanisms of activity. Each member of series 3 is substituted at 
the C-6 position by an isoprenyl chain made of 10 carbons. Compound 24 is fully 
saturated; whereas, 25 and 26 represent “R” and “S” enantiomers of the hydrocarbon 
chain (Figure 20). We propose to perform structure-activity relationship (SAR studies) on 
each of the newly synthesized coumarins, in nutrient rich and nutrient deprived 
conditions. Compounds will be tested against human pancreatic adenocarcinoma (PANC-
1) cell lines, as well as healthy human fibroblasts to determine the specificity of 
cytotoxicity. Next, we will consider the intrinsic fluorescence of coumarin derivatives. If 
detectably fluorescent, we propose to localize our novel coumarin derivatives within 
PANC-1 cells, or at the external cellular membrane. Further, we will analyze the 
morphological changes that PANC-1 cells undergo following exposure to coumarin 
derivatives.  
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Figure 20. Structures of (Series 3) compounds that test the influence of chirality and 
saturation on bioactivity. 24 is a fully saturated coumarin derivative. 25, the “R” 
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Results  
Synthesis of isoprenylated coumarins via Williamson Ether synthesis  
 
In order to evaluate the effect of isoprenyl positioning on coumarin-derived 
cytotoxicity against pancreatic adenocarcinoma (PANC-1) cell lines, we attempted to 
synthesize two novel series of isoprenylated coumarins from the starting materials 4-
hydroxycoumarin (22) and 4,7-dihydroxycoumarin (27).  
 
Figure 21. Chemical structure of the starting material, 4,7-dihydroxycoumarin. 
 
Previously, the Williamson Ether synthesis (Figure 19) was employed to synthesize 
similarly substituted coumarins from hydroxycoumarin starting materials in good yield 
[16]. So, we selected to use the same reaction procedure to alkylate 4-hydroxycoumarin 
(22) and 4,7-dihydroxycoumain (27). Given the structural similarities between the 
hydroxycoumarins and halogenated isoprenyl substrates, the same reaction procedure, 
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Synthesis of Series 1: C-4 monoprenylated coumarins  
The first attempt to alkylate 4-hydroxycoumarin (22) with 3,3-
dimethylallylbromide was unsuccessful (the reaction mechanism is depicted in Figure 
19). The reaction was set up using a previously described procedure and allowed to run 
overnight [16]. Reaction progress was monitored by thin layer chromatography. After 24 
hours, the formation of three new spots suggested that the reaction had been successful 
and the reaction was stopped. When the crude mixture was developed in a 7:3; Hexanes: 
Ethyl (H:E) acetate solvent system, the newly formed spots exhibited rf values of 0.32, 
0.56 and 0.79, respectively. The second spot (rf = 0.56) was suspected to be the desired 
product; though its rf value was higher than the expected value (0.41). To purify the 
suspected product band, the crude reaction material was loaded onto a preparative thin 
layer chromatography plate and developed in a 7:3; H:E solvent system. When the 
separated bands were visualized using ultraviolet light, no distinct bands were visible. 
Rather, there was one smeared band that spanned from the loading position to the solvent 
front. This smear was later attributed to excess N,N-dimethylformamide (DMF), the 
reaction solvent. Consequently, all organic material was retrieved from the plate and 
further concentrated in vacuo.  To confirm the viability of the retrieved material, the 
mixture was separated on a TLC plate. However, this separation produced six new spots, 
indicating that the products had decomposed prior to separation. To minimize excess 
solvent without significantly increasing the work-up time, half of the initial volume of 
DMF was used in later iterations of this reaction.  
The second attempt to alkylate 22 with 3,3-dimethylallylbromide produced three 
new spots on the reaction TLC. The crude mixture was again separated by preparative 
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TLC and the resultant bands exhibited rf values of 0.63, 0.43 and 0.15. The suspected 
product band (rf = 0.43) was recovered from the plate and identified as the desired 
product via 1H-NMR analysis (Appendix I). The purity and identity of this compound 
was later confirmed by 13C-NMR and high-resolution mass spectroscopy (HRMS) 
(Appendices II, IX, X).   
Upon successful completion of the first alkylation reaction, the same procedure 
was used to produce two similar coumarin derivates (17 and 18). Notably, geranyl 
bromide and farnesyl bromide, the halogenated electrophiles, are light sensitive. As such, 
reactions were run with minimal exposure to light. The first attempt to alkyate 4-
hydroxycoumarin with geranyl bromide was successful, and produced one new product 
spot with an expected rf value of 0.51  by TLC analysis. However, the crude mixture was 
mistakenly loaded onto a non-fluorescent preparative TLC plate and decomposed before 
it could be purified. The second attempt to synthesize 17 was successful. But, again, the 
isolation of the desired product failed. During the purification of the desired product via 
preparative TLC, the product band migrated with that of the decomposed bromide due to 
a wide loading band (Figure 22). Both bands were recovered and again separated using 
preparative TLC; though, the product decomposed before it was separated from the 
bromide band in a 10:1 Hexanes:Ethyl Acetate solvent system. Later preparative TLCs 
were loaded with thinner bands and exposed to heat prior to development to improve 
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Figure 22. Schematic diagram depicting desired product (indicated by dark gray) 
obscured by a wide band (indicated by light gray).  
 
The third attempt to synthesize and purify 17 was successful and its identity was 
confirmed by 1H-NMR analysis, 13C-NMR analysis and HRMS (Appendices III, IV, XI, 
XII). The same reaction procedure was used to synthesize 18, which was purified by 
preparative TLC and characterized by 1H-NMR analysis, 13C-NMR analysis and HRMS 
(Appendices V, VI, XIII, XIV). Characteristic peaks produced by the methylene 
(indicated in pink) and allylic (indicated by green and blue) protons of the isoprenoid 
moiety were used to identify the desired products (Figure 23).a  
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Figure 23.a Representative depiction of signature H-NMR peaks from previously 
characterized compounds. Blue color-coded protons represent distal allylic hydrogens, 
while green color-coded protons correspond to the allylic proton most proximal to the 
coumarin ring. The red color indicates methylene protons. The integration values are 
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Synthesis of C-4,7 diprenylated coumarins  
 
Synthesis of the diprenylated coumarins was attempted using the same 
Williamson ether synthesis as the monoprenylated series, with double the molar 
quantities of sodium hydroxide and isoprenyl halide (Figure 19). Reaction progress of the 
first diprenylation reaction, where two equivalents of 3,3-dimethylbromide were reacted 
with 4,7-dihydroxycoumarin, was, monitored via TLC. The formation of two new 
product spots (rf = 0.63 and 0.81) suggested that the reaction was successful, and the 
remaining two diprenylation reactions were set up in tandem. The C10 diprenylation 
reaction mixture produced three product spots (rf = 0.46, 0.56 and 0.77), suggesting that 
the reaction may have been successful. The rf value of the C5 diprenylation product, 19, 
was expected to be higher than the rf value of the monoprenylated C5 product (16), 0.41, 
so the third band (rf=0.81) was further characterized by H-NMR. Band 3 produced H-
NMR peaks that corresponded to each of the aromatic protons and had a peak at 4.8 ppm 
with an integration of 2, rather than the 4 anticipated methylene protons (Appendix VIII). 
In addition, the possible allylic peak appeared further upfield than expected (4.9 instead 
of 5.5 ppm)(Appendix VII). The product corresponding to band 2 was then characterized 
by H-NMR. Oddly, band 3 produced NMR peaks at the correct chemical shift (4.8 ppm), 
with the correct integration for the methylene protons, but no peak appeared around 5.5 
ppm, the chemical shift of the most up-field aromatic proton (Appendix VIII). Because 
the C5 diprenylation product could not be identified, the remaining diprenylation 
products were not further characterized or used in biological testing. Reaction TLC of the 
C-15 diprenylation product was prevented by the thickness of the reaction mixture, so it 
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is unclear how many products were formed. In contrast to previous reaction mixtures, the 
C-15 diprenylation product appeared as a thick, oily mass; whereas, previous reaction 
mixtures were colored liquids. This change in reaction mixture consistency may be 
explained by the significant hydrophobicity of 24 compared to other structures.  
To improve our understanding of the molecular mechanisms underlying 
coumarin-derived cytotoxicity, we also investigated the bioactivities of three compounds 
that were previously synthesized by another member of the Carrico-Moniz lab, Christine 
Chun ‘15 (24, 25, 26). This third series of compounds was engineered to test the 
influence of chirality and saturation on cytotoxicity against PANC-1 cells. All series 3 
compounds were characterized by H-NMR, C-NMR and HRMS (Appendices 15-26).   
 
Biological Results 
The bioactivities of each of the fully characterized coumarins were tested using a 
previously described colorimetric viability assay [16]. Mechanistically, the assay makes 
use of an endogenous dehydrodrogenase that reduces a yellow WST-8 salt, causing the 
dye to change color (orange) and absorb light at 450 nm. The enzyme is only present in 
viable cells, so WST-8 is not reduced in compromised cells. Absorbance at 450 nm, 
attributed to the reduced WST-8 dye, is directly proportional to the number of viable cells 
remaining in each well (Figure 24).  
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Figure 24. Schematic representing the mechanism underlying the colorimetric assay, 
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In the first cell viability assay, 16 and 17, were tested against PANC-1 cells in 
nutrient deprived (NDM) and nutrient rich (NRM) conditions. The results from the first 
viability assay were largely inconclusive, though they suggest pronounced cytotoxicity 
for compound 17 (Figure 25). To facilitate the analysis of cytotoxicity as a function of 
isoprenyl chain length, compounds are henceforth referred to, interchangeably, by the 
number of carbons in their isoprenyl tails (for instance, 16 has 5 carbons in its substituent 
and is thus referred to as C5).   
 
 
Figure 25. PANC-1 cell viability in nutrient-deprived and nutrient-rich conditions 
following 24-hour incubation with coumarin derivatives, 16 and 17. Error bars indicate 
standard error of the mean (SEM). C5 refers to 16. C10 refers to 17. NDM indicates 
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As anticipated, 16 had little effect on the viability of PANC-1 cells in NRM 
conditions (Figure 25). Surprisingly, though, at 100 µM both 16 and 17 were found to 
reduce cell viability to approximately 0%. Indeed, 17, exhibited potent cytotoxicity 
against PANC-1 cells in NDM at all concentrations, with an LC50 value of approximately 
3.5 µM. Significant variability within the readings suggests that there may have been 
issues with compound solubility. To resolve outstanding questions regarding the effect of 
17 and 18 on cell viability, the assay was repeated (Figure 26).  
 
 
Figure 26. PANC-1 cell viability in nutrient-deprived and nutrient-rich conditions 
following 24-hour incubation with coumarin derivatives, 16 and 17. Error bars indicate 
standard error of the mean (SEM). C5 refers to 16. C10 refers to 17. NDM indicates 
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To our satisfaction, the variability in each of the conditions diminished in the repeated 
assay, suggesting that we were able to resolve solubility issues from the previous assay. 
These data suggest a clear trend towards specific and pronounced cytotoxicity in nutrient-
deprived conditions, but not nutrient-rich conditions, for both 16 and 17. Compounds 16 
and 17 exhibited an LC50 value of 3.5 µM, corroborating the results of the first assay 
regarding 17 (Figure 25).  No consistent pattern was observed for the bioactivity of 16. 
This inconsistency underscored the need for yet an additional assay, the results of which 




Figure 27. PANC-1 cell viability in nutrient-rich media conditions following a 24-hour 
incubation period with 17. Error bars indicate standard error of the mean (SEM). C10 
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Figure 28. PANC-1 cell viability in nutrient-poor media conditions following a 24-hour 
incubation period with 17. Error bars indicate standard error of the mean (SEM). C10 
refers to 17. NDM indicates nutrient-deprived media. 
 
These data suggest that the activity of 17 varies between nutrient-rich and nutrient 
poor conditions and confirm its LC50 value (Figures 25 and 26). Interestingly, 
experimental variability, as measured by the standard error of the mean, also seems to 
vary between the two media conditions. This may suggest that compound 17 is more 
soluble in nutrient-deprived conditions than in nutrient-rich conditions. Alternatively, 
these findings may demonstrate that 17 has variable bioactivity in PANC-1 cells in 
nutrient-rich media conditions. Compound 18 exhibited an LC50 value of 6 µM against 
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Figure 29. PANC-1 cell viability in nutrient-deprived and nutrient-rich conditions 
following 24-hour incubation with coumarin derivative, 18. Error bars indicate standard 
error of the mean (SEM). C15 refers to compound 18.  
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Figure 30. PANC-1 cell viability in nutrient-deprived and nutrient-rich conditions 
following 24-hour incubation with coumarin derivative, 18. Error bars indicate standard 
error of the mean (SEM). C15 refers to compound 18. NDM indicates nutrient-deprived 
media and NRM indicates nutrient-rich media.  
 
It is interesting to note that variability was high in the C5 and C10 assays, but minimal in 
the C15 assays. This trend, in which longer isoprenyl tails lead to less variability, may 
suggest that the variability was not due to solubility alone.  
 
 The fully saturated coumarin derivative, 24, produced inconsistent results that 
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Figure 31. PANC-1 cell viability in nutrient-deprived and nutrient-rich conditions 
following 24-hour incubation with coumarin derivative, 24 (CC-1-3). Error bars indicate 
standard error of the mean (SEM). NDM indicates nutrient-deprived media and NRM 
indicates nutrient-rich media.  
 
Unfortunately, the variation in these data make it difficult to draw conclusive results. 
Nevertheless, even high concentrations of the compound did not significantly reduce cell 
viability by more than 50%, suggesting that complete saturation reduces cytotoxicity of 
coumarin derivatives (Figure 31). 
 
The “R” enantiomer, 25, also did not exhibit a concentration-dependent effect on PANC-
1 viability. In fact, the cytotoxicity trend is the opposite of what was expected—
cytotoxicity decreased with increasing concentration (Figure 32). Again, variability in the 
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Figure 32. PANC-1 cell viability in nutrient-deprived and nutrient-rich conditions 
following 24-hour incubation with coumarin derivative, 25 (CC-1-19). Error bars indicate 
standard error of the mean (SEM). NDM indicates nutrient-deprived media and NRM 
indicates nutrient-rich media.  
 
Alternatively, the “S” enantiomer appeared completely innocuous in both nutrient-
deprived and nutrient-rich conditions (Figure 33). In both media conditions, cell viability 
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Figure 33. PANC-1 cell viability in nutrient-deprived and nutrient-rich conditions 
following 24-hour incubation with coumarin derivative, 26 (CC-1-23). Error bars indicate 
standard error of the mean (SEM). NDM indicates nutrient-deprived media and NRM 
indicates nutrient-rich media.  
 
In sum, the C10 monoprenylated compound exhibited the lowest LC50 value (3.5 µM) of 
all the compounds tested against PANC-1 cells in nutrient-deprived media. The second 
most toxic compound was the C15 monoprenylated product with an LC50 value of 6 µM. 
No definitive trend was identified for the C5 monoprenylated product. Our preliminary 
work suggests that none of the series 3 compounds demonstrated concentration-
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Discussion 
The present study sought to describe the influence of substitution position, 
substituent chain length (Series 1) and diprenylation (Series 2) on the cytotoxicity of 
simple coumarin-derivatives against PANC-1 cells in nutrient-deprived and nutrient-rich 
media conditions. To this end, we synthesized a novel series of coumarin derivatives 
substituted with isoprenyl moieties of varying length at the C-4 position.  Moreover, we 
attempted to synthesize a series of diprenylated coumarins, substituted with varying 
isoprenyl moieties at the C-4 and C-7 positions. The bioactivity of previously 
characterized compounds (Series 3) was also considered as a proxy for the influence of 
chirality and saturation on cytotoxicity. The underlying cause for pancreatic cancers’ 
resistance to nutrient deprivation remains unknown. However, this austerity in nutrient-
poor environments creates a novel biochemical target in the treatment of pancreatic 
cancer. Structure-activity relationship studies, like this one, pose another way of 
understanding this resistance to nutrient-deprivation and thus using it to develop novel 
therapies.  
 Herein, we report the synthesis and characterization of a novel series of 
monoprenylated coumarins substituted at the C4 position with 5, 10 and 15 carbon 
isoprenylated chains. Each of these compounds was fully characterized by 1H-NMR, 13C-
NMR and HRMS prior to biological testing. The bioactivities of each of these 
compounds was assayed against PANC-1 cells in nutrient-rich and nutrient-deprived 
conditions and each of these assays was replicated at least twice. We attempted to 
synthesize an analogous series of diprenylated coumarins; however, the Williamson ether 
synthesis underwent an unexpected side reaction and the formation of the desired product 
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was inconclusive. The monoprenylated series (Series 1), in addition to three previously 
synthesized compounds, were tested in our viability assay to determine the influence of 
isoprenyl chain positioning, saturation and chirality on cytotoxicity.  
Of the compounds tested, coumarin derivatives substituted at the C-4 position, 
with substituents of 10 or 15 carbons in length proved most cytotoxic. Compounds 17 
and 18 exhibited LC50 values of 3.5 and 5 µM, respectively. This finding is surprising 
given our previous work that has directly correlated chain length with cytotoxicity [16]. 
Nevertheless, multiple repetitions of the relevant assays have confirmed our initial 
finding that the C10 compound is more cytotoxic than the C15 derivative (Figures 25, 26, 
28-30). This discrepancy may be explained by the fact that substitution position does, 
indeed, influence bioactivity and potentially the underlying mechanism of action. 
Previous work has suggested that derivatives with short isoprenyl substituents (of 5 
carbons, specifically) are generally nontoxic to PANC-1 cells in nutrient-deprived media 
[16]. Our preliminary findings, while variable, suggest that the C5 derivative has some 
cytotoxicity against PANC-1 cells in NDM. The results of the first assay were 
inconclusive, though the C5 compound was toxic to cells at 100 µM (Figure 25). 
Surprisingly, the second assay indicated an LC50 value of approximately 3.5 µM (Figure 
26). Future work will replicate biological assays with the C5 compound to confirm its 
bioactivity against PANC-1 cells during nutrient deprivation.  
Upcoming studies will propose novel synthetic schemes for the diprenylation 
reaction (Series 2). Further characterization of our previously formed side products will 
inform these variations. The successful synthesis of a series of diprenylated products will 
contribute to our understanding of what structural components underlie coumarin-derived 
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cytotoxicity, by further probing the influence of size, hydrophobicity and substitution 
position on bioactivity. Preliminary biological results from probing the activity of series 3 
compounds suggest that chirality and saturation may not be critical structural elements 
for cytotoxicity. Both enantiomers of the C10 coumarin, substituted at the C-6 position, 
compounds 25 and 26, and its fully saturated analogue, compound 24, reduced cell 
viability by no more than 50%, even at concentrations of 100 µM (Figures 31-33). These 
findings were not duplicated and are therefore not yet conclusive.  Future assays are 
therefore necessary to confirm these initial results.    
While the development of coumarin derivatives as anti-pancreatic cancer agents is 
still in its infancy, this study provides valuable information about the structural elements 
that are necessary for coumarin-derived bioactivity. Our findings confirm that simple 
coumarin-derivatives can exhibit robust cytotoxicity against PANC-1 cells nutrient 
deprived conditions at low micromolar concentrations. We posit that increasing 
substituent length, and thereby hydophobicity, may not be the sole factor in increasing 
cytotoxicity. Indeed, 17, a coumarin with an isoprenoid group of 10 carbons in length 
was more toxic than derivatives with longer isoprenyl groups at the C-4 or C-7 position 
(Figure 28, [16]). As such, the observed increase in cytotoxicity appears to result from a 
delicate balance of substituent length/hydophobicity, saturation and proper positioning on 
the coumarin scaffold. In this study, structural analogs with isoprenyl substituents of the 
same length as 17 (compounds 24, 25 and 26, which were fully saturated or partially 
saturated and chiral) reduced cell viability by only 50%.  
The physiological target of these coumarin derivatives remains unclear. Of the 
compounds analyzed in this study, the C15 derivative, compound 18, was selected for 
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future fluorescence studies due to its robust intrinsic UV-fluorescence (data not shown). 
Future work will make use of this intrinsic fluorescence to localize coumarins within the 
cell or at the membrane surface. The first step towards identifying the physiological 
target of our compounds will be to determine the peak excitation and emission 
wavelengths for one of our synthesized coumarins (likely the C15 monoprenylated 
derivative). Once we are able to selectively excite and detect our compound, we can 
monitor compound fluorescence while quenching fluorescence outside the cell using dye. 
If the compound remains detectable after the fluorescence quench, it suggests that the 
coumarin derivatives do, indeed, cross the cell membrane and enter the cell.  
In the evolution of coumarin-derived therapies in the treatment of pancreatic 
cancer, a number of outstanding control experiments remain: 
 To confirm compound solubility over time and verify our biological data, we 
propose measuring compound concentration in the media/DMSO solution, using Beer’s 
Law. Verifying compound solubility could also support or refute the suggestion that 
variable compound solubility is producing variable biological results (as in the case of the 
C5 monoprenylated product).  
Future work will also confirm the specificity of coumarin-derived cytotoxicity 
against pancreatic cancer cells by testing these compounds against non-cancerous cells, 
specifically healthy human fibroblasts (WI-38, ATCC).  We also propose to assay our 
compounds against other lines of pancreatic cancer cells to confirm that this cytotoxicity 
is not the result of something unique to PANC-1 cells.   
To improve the accuracy of our biological assay and produce results that are more 
physiologically relevant, we propose excluding data that does not meet specific 
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constraints. For instance, it is expected that the 0 µM control (which contains cells, media 
and kit) should absorb more energy at 450 nm than the blank control (which contains 
only media and kit) due to the presence of cells. However, some of our data violates this 
assumption, leading to impractically high cell viabilities (300%+) and negative viabilities 
(Figures 31 and 32).  Whatever the reason for these discrepancies, they suggest that the 
colorimetric assay is not working as expected. The WST-8 colorimetric assay depends on 
the activity of a dehydrogenase associated with the cellular energy production. This 
pathway may be compromised in nutrient-deprived conditions, skewing the results of our 
biological assays. It is critical to confirm that dehydrogenase activity is not altered in 
nutrient deprived conditions, independent of coumarin bioactivity, altering our results. To 
circumvent these problems, we suggest measuring cell viability using other methods. 
Moreover, we are interested in whether or not cells shocked into nutrient deprivation (as 
is currently the case in our biological assay) respond to coumarin derivatives in same way 
as those that are accustomed to nutrient deprivation. To better simulate the tumor 
microenvironment, we suggest co-culturing cancerous and healthy cells together, and 
inducing the growth of tumor cells into spheroids (or 3D balls of cells). The use of co-
cultured spheroids would allow us to model coumarin diffusion into the tumor core, while 
exploring compound interactions with the two cell types. The completion of the 
aforementioned controls will provide robust evidence for the specific bioactivity of 
coumarin derivatives against pancreatic cancer cells in nutrient-poor conditions. This 
specific cytotoxicity can then be harnessed as a novel biochemical treatment for 
pancreatic cancer tumors.  
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Conclusion 
 
Herein, we report the synthesis of a novel series of monoprenylated coumarins, 
substituted at the C-4 position of the coumarin scaffold with 5, 10 and 15 carbon tails. 
The cytotoxicity of these coumarin derivatives was tested against pancreatic 
adenocarcinoma (PANC-1) cell lines, in nutrient-rich and nutrient-poor conditions. These 
derivatives proved toxic in nutrient-deprived conditions and innocuous in nutrient-rich 
conditions. Coumarins with isoprenyl tails of 10 and 15 carbons in length exhibited LC50 
values of 3.5 and 6 µM, respectively, in nutrient-deprived conditions. We attempted to 
synthesize a second series of diprenylated coumarins with substituents at the C-4 and C-7 
positions; however, our initial syntheses were unsuccessful. We also tested the bioactivity 
of a third series of coumarins substituted at the C-6 position with fully saturated and 
partially saturated, chiral tails. Series 3 compounds did not reduce cell viability by more 
than 50%, even at concentrations of 100 µM.  
Previously, our lab has shown that isoprenyl chain length is directly correlated 
with cytotoxicity in coumarins substituted at the C-7 position [16].  Nevertheless, the 
results of the present study suggest that the influence of chain length on cytotoxicity is 
qualified by substituent position. Indeed, coumarins substituted at the C-4 position with a 
10 carbon tail proved more toxic than derivatives substituted at the C4 and C7 positions 
with 15 and 20 carbon tails, respectively [16]. Moreover, these results suggest that 
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 Experimental section  
General Protocols 
1H and 13C NMR spectra were recorded on a 
Bruker 300 Fourier transform instrument as dilute solutions in acetone-d6 at 300 MHz 
(1H NMR) or 75 MHz (13C NMR). Chemical shifts were reported in δ (ppm) relative to 
tetramethylsilane. Reactants, reagents, and solvents were obtained from Sigma-Aldrich 
and were used as received. Synthesized final compounds were checked for purity by TLC 
analysis, 1H NMR and 13C NMR. High-resolution mass spectra (HRMS) and low-
resolution mass spectra (LRMS) were performed on a 70-VSE or QTof Ultima mass 
spectrometer at the University of Illinois at Urbana-Champaign. Silica gel 60, F254, pre- 
coated glass TLC plates purchased from EMD were used for all (non-preparative) thin 
layer chromatography. Preparative thin layer chromatography was performed using pre- 
coated plates with 1000 microns thick silica gel coating purchased from Sigma Aldrich. 
Nutrient-rich and nutrient-deprived media were made from scratch based off of a 
previously published study[8]. The ingredients may be found in Appendix XXVII. In all 




Cell culture protocol 
 
All cell lines (PANC-1 and WI-38) were obtained from the ATCC and cultured in a 5% 
humidified CO2 incubator at 37°C in complete DMEM (Sigma, Appendix XXVII). Cells 
were grown until a single layer of confluent cells had adhered to the flask and then were 
passaged into a new flask. The passaging procedure is as follows: First, old media is 
discarded via vacuum suction. Confluent cells are washed with room-temperature PBS, 
which is then discarded.  Subsequently, 2-5 mL of thawed trysin-EDTA solution is 
filtered and added to the flask, prior to incubation at 37°C for 2-3 minutes. Once the 
majority of the cells are detached from the flask, the solution is transferred to a centrifuge 
tube and spun at 1000 rpm for 3 minutes. The resultant supernatant is discarded and the 
cell pellet is thoroughly resuspended in 2-4 mL of complete DMEM (Sigma).  Cell 
suspension is transferred to a sterile flask and complete DMEM is added, as appropriate, 
prior to overnight incubation. The following day, cells are checked for attachment to the 






	   53	  
Experimental 
Synthesis of 4-((3-methylbut-2-en-1-yl)oxy)-2H-chromen-2-one (16) 
 
 
An oven-dried 50mL round bottom flask was prepared with a magnetic stirring bar, a 
rubber septum cover, and a nitrogen inlet. 4-hydroxycoumarin (24) (168 mg, 1.03 mmol) 
and 4 mL of anhydrous N,N-dimethylformamide (DMF) were added to the round bottom 
flask, which was again evacuated and purged with nitrogen. The solution was stirred and 
cooled to 0ºC in a salt-ice bath. Sodium hydride (48 mg of 60% mineral oil suspension, 2 
mmol) was added to the flask, at which point H2 gas began to form. The solution was 
then stirred at 0ºC for 30 minutes, under nitrogen gas. 3,3-dimethyl bromide (250 µL, 
1.29 g/mL, 2.1 mmol) in 1 mL of anhydrous DMF was cooled to 0ºC and added drop-
wise to the flask through the rubber septum using a syringe. The reaction mixture was left 
to stir under nitrogen and warm back to room temperature overnight. The desired product 
was obtained by preparative thin layer chromatography using a solvent system of 70% 
hexanes and 30% ethyl acetate (rf = 0.43). The purified product was verified by NMR 
spectroscopy (1H-NMR, 13C-NMR) and high-resolution mass spectrometry (HRMS). 1H-
NMR (300 MHz, (CD3)2CO): ∂ 1.81-2.06 (10H), 4.81-4.84 (s, 2H), 5.61 (m, 1H), 5.78 (s, 
1H), 7.29 – 7.35 (m, 2H), 7.60 – 7.66 (m, 1H), 7.81-7.84 (m, 1H); 13C-NMR (75 MHz, 
(CD3)2CO): ∂ 18.14, 18.31, 25.85, 26.66, 67.19, 91.47, 116.73, 117.03, 117.27, 118.81, 
123.15, 123.88, 124.52, 125.70, 132.21, 133.27, 140.63, 154.34, 162.30, 165.87. HRMS 
(ESI) Calcd. for C14H15O3: 231.1021; found: 231.1022. 
 
 
Synthesis of (E)-4-((3,7-dimethylocta-2,6-dien-1-yl)oxy)-2H-chromen-2-one (17) 
 
An oven-dried 50mL round bottom flask was prepared with a magnetic stirring bar, a 
rubber septum cover, and a nitrogen inlet. 4-hydroxycoumarin (24) (172 mg, 1.06 mmol) 
and 2 mL of anhydrous N,N-dimethylformamide (DMF) were added to the round bottom 
flask, which was again evacuated and purged with nitrogen. The solution was stirred and 
cooled to 0ºC in a salt-ice bath. Sodium hydride (51 mg of 60% mineral oil suspension, 
2.1 mmol) was added to the flask, at which point H2 gas began to form. The solution was 
then stirred at 0ºC for 30 minutes, under nitrogen gas. Geranyl bromide (400 µL, 1.29 
g/mL, 2.3 mmol) in 1 mL of anhydrous DMF was cooled to 0ºC and added drop-wise to 
the flask through the rubber septum using a syringe. The reaction mixture was left to stir 
under nitrogen and warm back to room temperature overnight. The desired product was 
obtained by preparative thin layer chromatography using a solvent system of 70% 
hexanes and 30% ethyl acetate (rf = 0.56). The purified product was verified by NMR 
spectroscopy (1H-NMR, 13C-NMR) and high-resolution mass spectrometry (HRMS). 1H-
NMR (300 MHz, (CD3)2CO): ∂ 1.61 – 2.16 (17H), 4.85 – 4.87 (s, 2H), 5.12 (m, 1H), 5.60 
(d, 1H), 5.78 (s, 1H); 7.29 – 7.35 (m, 2H), 7.60 – 7.66 (m, 1H), 7.81-7.84 (m, 1H). 13C-
NMR (75 MHz, (CD3)2CO): ∂ 16.47, 17.71, 23.86, 25.81, 27.37, 40.49, 105.28, 116.87, 
118.54, 122.66, 124.20, 125.11, 129.64, 131.65, 131.88, 132.00, 136.44, 153.55, 163.98. 
HRMS (EI) Calcd. for C19H22O3: 298.1569; found: 298.1570. 
 




An oven-dried 25mL round bottom flask was prepared with a magnetic stirring bar, a 
rubber septum cover, and a nitrogen inlet. 4-hydroxycoumarin (24) (168 mg, 1.03 mmol) 
and 1 mL of anhydrous N,N-dimethylformamide (DMF) were added to the round bottom 
flask, which was again evacuated and purged with nitrogen. The solution was stirred and 
cooled to 0ºC in a salt-ice bath. Sodium hydride (60 mg of 60% mineral oil suspension, 
2.5 mmol) was added to the flask, at which point H2 gas began to form. The solution was 
then stirred at 0ºC for 30 minutes, under nitrogen gas. Farnesyl bromide (541 µL, 1.05 
g/mL, 1.9 mmol) in 1 mL of anhydrous DMF was cooled to 0ºC and added drop-wise to 
the flask through the rubber septum using a syringe. The reaction mixture was left to stir 
under nitrogen and warm back to room temperature overnight. The desired product was 
obtained by preparative thin layer chromatography using a solvent system of 70% 
hexanes and 30% ethyl acetate (rf = 0.57). The purified product was verified by NMR 
spectroscopy (1H-NMR, 13C-NMR) and high-resolution mass spectrometry (HRMS). 1H-
NMR (300 MHz, (CD3)2CO): ∂ 1.54 – 2.17 (26H), 4.85 – 4.87 (s, 2H), 5.15 (d, 2H), 5.60 
(1H), 5.78 (s, 1H), 7.30 – 7.35 (m, 2H), 7.60 – 7.66 (1H), 7.81-7.84 (m, 1H); 13C-NMR 
(75 MHz, (CD3)2CO): ∂ 16.13, 16.44, 16.78, 17.73, 23.31, 25.85, 26.77, 27.40, 28.32, 
37.89, 39.87, 40.12, 40.42, 43.29, 67.20, 91.50, 111.28, 116.71, 118.11, 118.76, 123.86, 
124.16, 124.48, 124.66, 125.10, 125.68, 129.13, 131.64, 133.25, 136.03, 143.76, 146.88, 
154.32, 162.28, 165.82. HRMS (EI) Calcd. for C24H30O3: 366.2195; found: 366.2196. 
 
Synthesis of 4,7-bis((3-methylbut-2-en-1-yl)oxy)-2H-chromen-2-one (KE-1-79, 19) 
An oven-dried 50mL round bottom flask was prepared with a magnetic stirring bar, a 
rubber septum cover, and a nitrogen inlet. 4,7-dihydroxycoumarin (Z) (180 mg, 1.01 
mmol) and 1 mL of anhydrous N,N-dimethylformamide (DMF) were added to the round 
bottom flask, which was again evacuated and purged with nitrogen. The solution was 
stirred and cooled to 0ºC in a salt-ice bath. Sodium hydride (80 mg of 60% mineral oil 
suspension, 2 mmol) was added to the flask, at which point H2 gas began to form. The 
solution was then stirred at 0ºC for 30 minutes, under nitrogen gas. 3,3-dimethyl bromide 
(462 µL, 1.29 g/mL, 2.0 mmol) in 1 mL of anhydrous DMF was cooled to 0ºC and added 
drop-wise to the flask through the rubber septum using a syringe. The reaction mixture 
was left to stir under nitrogen and warm back to room temperature, overnight. Reaction 
products were purified using preparative thin layer chromatography. The desired product 
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Synthesis of 7-(((E)-3,7-dimethylocta-2,6-dien-1-yl)oxy)-4-(((Z)-3,7-dimethylocta-2,6-
dien-1-yl)oxy)-2H-chromen-2-one (KE-1-83, 20) 
An oven-dried 50mL round bottom flask was prepared with a magnetic stirring bar, a 
rubber septum cover, and a nitrogen inlet. 4,7-dihydroxycoumarin (Z) (182 mg, 1.02 
mmol) and 1 mL of anhydrous N,N-dimethylformamide (DMF) were added to the round 
bottom flask, which was again evacuated and purged with nitrogen. The solution was 
stirred and cooled to 0ºC in a salt-ice bath. Sodium hydride (80 mg of 60% mineral oil 
suspension, 2.0 mmol) was added to the flask, at which point H2 gas began to form. The 
solution was then stirred at 0ºC for 30 minutes, under nitrogen gas. Geranyl bromide (673 
µL, 1.29 g/mL, 2.0 mmol) in 1 mL of anhydrous DMF was cooled to 0ºC and added 
drop-wise to the flask through the rubber septum using a syringe. The reaction mixture 
was left to stir under nitrogen and warm back to room temperature overnight. Reaction 
products were purified using preparative thin layer chromatography. The desired product 




3,7,11-trimethyldodeca-2,6,10-trien-1-yl)oxy)-2H-chromen-2-one (KE-1-84, 21) 
An oven-dried 50mL round bottom flask was prepared with a magnetic stirring bar, a 
rubber septum cover, and a nitrogen inlet. 4,7-dihydroxycoumarin (Z) (190 mg, 1.06 
mmol) and 1 mL of anhydrous N,N-dimethylformamide (DMF) were added to the round 
bottom flask, which was again evacuated and purged with nitrogen. The solution was 
stirred and cooled to 0ºC in a salt-ice bath. Sodium hydride (80 mg of 60% mineral oil 
suspension, 2 mmol) was added to the flask, at which point H2 gas began to form. The 
solution was then stirred at 0ºC for 30 minutes, under nitrogen gas. Farnesyl bromide 
(1.08 mL, 1.05 g/mL, 2.0 mmol) in 1 mL of anhydrous DMF was cooled to 0ºC and 
added drop-wise to the flask through the rubber septum using a syringe. The reaction 
mixture was left to stir under nitrogen and warm back to room temperature overnight. 
Reaction products were purified using preparative thin layer chromatography. The 
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Synthesis of 6-((3,7-dimethyloctyl)oxy)-2H-chromen-2-one (22, CC-I-3)*: 
An oven dried 50mL round bottom flask was prepared with a magnetic stirring bar, a 
rubber septum cover, and a nitrogen inlet. 6-hydroxycoumarin (114 mg, 0.7 mmol) and 4 
mL of anhydrous N,N-dimethylformamide (DMF) were added to the round bottom flask. 
The solution was stirred and cooled to 0ºC in a salt-ice bath. Sodium hydride (28 mg of 
60% mineral oil suspension, 0.7 mmol) was added to the flask at which point the solution 
turned color from yellow to orange. The solution was kept stirring at 0ºC for 30 minutes. 
1-Bromo-3,7-dimethyloctane (344.4 µL, 1.66 mmol) in 1 mL of DMF was cooled to 0ºC 
and added drop-wise to the flask through the rubber septum using a syringe. The reaction 
mixture was left stirring under nitrogen to warm back to room temperature over 14 hours. 
The desired product was obtained through preparative thin layer chromatography using a 
7:3 Hexanes:Ethyl acetate solvent system. The purified product was verified by NMR 
spectroscopy (1H-NMR, 12C-NMR) and high-resolution mass spectrometry (HRMS). 1H-
NMR (300 MHz, CD3COCD3): ∂ 0.95-1.86 (19H), 4.08 (t, 2H), 6.40 (d, 1H, J=9Hz), 
7.17 (m, 2H), 7.27 (s, 1H), 7.92 (d, 1H, J=9Hz); 13C-NMR (75 Hz, CD3COCD3): ∂ 19.91, 
22.87, 22.97, 25.13, 25.37, 36.60, 37.92, 39.93, 67.54, 111.97, 117.58, 118.47, 120.28, 
120.56, 129.10, 144.35, 149.19, 156.44, 160.77. HRMS (EI) Calcd. for C19H26O3: 




Synthesis of (R)-6-((3,7-dimethyloct-6-en-1-yl)oxy)-2H-chromen-2-one (23, CC-I-19)*: 
An oven dried 50mL round bottom flask was prepared with a magnetic stirring bar, a  
rubber septum cover, and a nitrogen inlet. 6-hydroxycoumarin (114 mg, 0.7 mmol) and 4 
mL of anhydrous N,N-dimethylformamide (DMF) were added to the round bottom flask. 
The solution was stirred and cooled to 0ºC in a salt-ice bath. Sodium hydride (28 mg of 
60% mineral oil suspension, 0.7 mmol) was added to the flask. The solution was kept 
stirring at 0ºC for 30 minutes. 8-Bromo-2,6-dimethyl-2-octene-(R)-(-)-citronellyl 
bromide (327.8 µL, 1.66 mmol) in 1 mL of DMF was cooled to 0ºC and added drop-wise 
to the flask through the rubber septum using a syringe. The reaction mixture was left 
stirring under nitrogen to warm back to room temperature over 14 hours. The desired 
product was obtained through preparative thin layer chromatography using a 7:3 
Hexanes:Ethyl acetate solvent system. The purified product was verified by NMR 
spectroscopy (1H-NMR, 12C-NMR) and high-resolution mass spectrometry (HRMS). 1H-
NMR (300 MHz, CD3COCD3): ∂ 1.30-2.07 (16H), 4.09 (t, 2H), 5.11 (m, 1H), 6.40 (d, 
1H, J=6Hz), 7.22 (m, 3H), 7.92 (d, 1H, J=6Hz); 13C-NMR (75 Hz, CD3COCD3): ∂ 17.72, 
19.84, 25.86, 26.35, 36.51, 38.53, 67.37, 112.37, 117.33, 118.43, 120.24, 120.52, 125.66, 
129.07, 131.51, 144.29, 149.16, 156.40, 160.72. HRMS (EI) Calcd. for C19H24O3: 
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Synthesis of (S)-6-((3,7-dimethyloct-6-en-1-yl)oxy)-2H-chromen-2-one (24, CC-I-23)*:  
An oven dried 50mL round bottom flask was prepared with a magnetic stirring bar, a 
rubber septum cover, and a nitrogen inlet. 6-hydroxycoumarin (86 mg, 0.5 mmol) and 4 
mL of anhydrous N,N-dimethylformamide (DMF) were added to the round bottom flask. 
The solution was stirred and cooled to 0ºC in a salt-ice bath. Sodium hydride (21.2 mg of 
60% mineral oil suspension, 0.5 mmol) was added to the flask. The solution was kept 
stirring at 0ºC for 30 minutes. 8-Bromo-2,6-dimethyl-2-octene-(S)-(+)-citronellyl 
bromide (327.8 µL, 1.66 mmol) in 1 mL of DMF was cooled to 0ºC and added drop-wise 
to the flask through the rubber septum using a syringe. The reaction mixture was left 
stirring under nitrogen to warm back to room temperature over 14 hours. The desired 
product was obtained through preparative thin layer chromatography using a 7:3 
Hexanes:Ethyl acetate solvent system. The purified product was verified by NMR 
spectroscopy (1H-NMR, 12C-NMR) and high-resolution mass spectrometry (HRMS). 1H-
NMR (300 MHz, CD3COCD3): ∂ 1.30-2.07 (16H), 4.09 (t, 2H), 5.11 (m, 1H), 6.40 (d, 
1H, J=9Hz), 7.22 (m, 3H), 7.92 (d, 1H, J=9Hz); 13C-NMR (75 Hz, CD3COCD3): ∂ 17.72, 
19.81, 26.19, 26.36, 37.40, 39.69, 67.52, 111.52, 117.32, 118.46, 120.26, 120.54, 125.62, 
129.08, 131.54, 143.98, 149.18, 156.42, 160.75. HRMS (EI) Calcd. for C19H24O3: 
300.1725; found: 300.1723.  
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Viability Assay 
All cell lines were cultured in complete DMEM (Sigma Aldrich) at 37°C in 5% CO2. In 
the interest of consistency, cell passage number was recorded for all cell lines and only 
cells within P39-P48 were used in viability assays. On the first day of the viability assay, 
cell density was determined and cells were seeded into a 96-well clear bottom plate at a 
density of 2.3x104 cells per well. Cells were left to incubate for 24 hours. Meanwhile, 
fully characterized compounds were vacuum-dried for a minimum of two hours and 
dissolved in dimethyl sulfoxide (DMSO). On the second day of the assay, the 
DMSO/compound mixture was then diluted in nutrient-rich or nutrient-deprived media 
(media recipe can be found in Appendix XII) to a concentration of 1.1 mM in 5.5% 
DMSO.  The cells were then washed with 1x phosphate buffer solution (PBS). Next, the 
compound solution was added to each well and further diluted to a final compound 
concentration of 100, 50, 25, 12.5 or 6.25 µM. Each concentration/media condition was 
run in triplicate. Cells were incubated with coumarin derivatives for 24 hours. Following 
the incubation period, the cells were, again, washed with 1x PBS. In preparation for the 
colorimetric viability assay, cells were incubated with complete DMEM (Sigma) and 
WST-8 kit (Dojindo). After three hours, the absorbance of each well at 450 nm was 
determined.  Cell viability was calculated, per well, using the following equation: 
 
(Abs450 – Blank2)/(Blank1-Blank2) 
 
where Blank1 corresponds to absorbance at 450 nm in wells containing cells, media, 
WST-8 kit and 5.5% DMSO and Blank2 refers to the absorbance at 450 nm in wells 
containing only the media and WST-8 kit.  
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Appendix I 
H1-NMR in acetone-d6 of  
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Appendix II 
C13-NMR in acetone-d6 of  
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Appendix III 
H1-NMR in acetone-d6 of   
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Appendix IV 
C13-NMR in acetone-d6 of   
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Appendix V 
H1-NMR in acetone-d6 of 4-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)oxy)-2H-
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Appendix VI 
C13-NMR in acetone-d6 of 4-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)oxy)-
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Appendix VII 
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Appendix VIII 
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Appendix IX 
HRMS (Q-tof)  of 
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Appendix X 
HRMS (Q-tof)  of 
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Appendix XI 
HRMS (EI)  of 





Elemental Composition Report                                                                                                                                Page 1
Single Mass Analysis 
Tolerance = 5.0 mDa   /   DBE: min = -1.5, max = 50.0
Element prediction: Off 
Monoisotopic Mass, Odd and Even Electron Ions
12 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass)
Elements Used:
C: 0-50    H: 0-100    O: 2-4    
m/z




 Dora Carrico-Moniz, KE-1-59-2




Minimum:                                    -1.5
Maximum:                  5.0      10.0     50.0
Mass       Calc. Mass     mDa      PPM      DBE      i-FIT      Formula
298.1570   298.1569       0.1      0.3      9.0      5546065.0  C19  H22  O3 
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Appendix XII 
HRMS (EI)  of 
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Appendix XIII 







Elemental Composition Report                                                                                                                                Page 1
Single Mass Analysis 
Tolerance = 5.0 mDa   /   DBE: min = -1.5, max = 50.0
Element prediction: Off 
Monoisotopic Mass, Odd and Even Electron Ions
15 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass)
Elements Used:
C: 0-50    H: 0-100    O: 2-4    
m/z




 Dora Carrico-Moniz, KE-1-75-3
 KE-1-75-3a 2488 (14.499)  TOF MS EI+ 
 1.91e+003
366.2196
364.2043363.9736 366.0114365.1998364.9107 365.8457 367.2223367.0289366.6843 368.0572367.3788 369.0766368.2195
Minimum:                                    -1.5
Maximum:                  5.0      10.0     50.0
Mass       Calc. Mass     mDa      PPM      DBE      i-FIT      Formula
366.2196   366.2195       0.1      0.3      10.0     3.1        C24  H30  O3 
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Appendix XIV 
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Appendix XV 
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Appendix XVI 
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Appendix XVII 
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Appendix XVIII 
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Appendix XIX 
H1-NMR in acetone-d6  of  
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Appendix XX 
C13-NMR in acetone-d6  of  
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Appendix XXI 
HRMS (EI) for  
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Appendix XXII 
HRMS (EI) for  
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Appendix XXIII 
H1-NMR in acetone-d6  of  
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Appendix XXIV 
C13-NMR in acetone-d6  of  











HRMS (EI) of 














HRMS (EI) for  
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Appendix XXVII 
Preparation of complete DMEM from powder 
 
To prepare complete DMEM, one bottle of Dulbecco Modified Eagle’s Minimum 
Essential Media (Sigma Aldrich) was dissolved in 800 mL of HPLC-purified water. 
Sodium bicarbonate (49.1 mL) and 100x anti-biotic/anti-fungal solution (10 mL) were 
then added to the solution and the total volume was brought to 900 mL using HPLC 
water and adjusted to a pH of 7.4. Half of this mixture, 450 mL, was then combined with 
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Appendix XXVIII 
Composition of media made from scratch: 
 CaCl2 (0.265 mg/mL) 
 FeNO3 (0.001 mg/mL)  
 KCl: (0.400 mg/mL) 
 MgSO4: (0.200 mg/mL) 
 NaCl: (6.400 mg/mL) 
 NaHCO3 (0.700 mg/mL) 
 NaH2PO: (0.125 mg/mL) 
 Phenol red: (0.015 mg/mL) 
 HEPES buffer: (5.958 g/L) 
 MEM vitamin solution (1%) 
 D-glucose (1 g/L)* 
 L-glutamine (2 mM)*  
 MEM amino acids solution (2%)* 
 MEM nonessential amino acids solution (1%)* 
 FCS (10%)* 
 
*Indicates components that are absent in the nutrient-deprived media 
 
Media recipes are based off of a previously published study [8]. All components were 
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